ETNB

89bio, Inc. [ETNB] Stock Forecast

Q: What is 89bio, Inc. stock symbol ?

89bio, Inc. is a US stock, located in San francisco of Ca and trading under the symbol ETNB

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ETNB Stock Summary

The Moving Average Convergence Divergence (MACD) for ETNB recently turned positive (within last 10 days).

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 95.03%

ETNB has less than 1 year of cash runway

Top 10 Correlated Stocks

ETNB

In the News

10:31 01 Apr 2023 ETNB

Ra Capital Management Now Owns 18% of 89bio

Fintel reports that Ra Capital Management has filed a 13D/A form with the SEC disclosing ownership of 12.88MM shares of 89bio Inc (ETNB).

09:02 01 Apr 2023 ETNB

Tech Stocks Are Surging

The Nasdaq 100 is on a tear

11:40 01 Apr 2023 ETNB

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH

NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.

10:11 01 Apr 2023 ETNB

89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering

89bio announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25 The post 89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering appeared first on Pulse 2.0.

10:57 01 Apr 2023 ETNB

Why Shares of 89bio Soared This Week

89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH drug has been approved yet by the FDA.

07:21 01 Apr 2023 ETNB

89bio's public stock offering upsized by 38%, priced at a 4% discount

89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The company said it sold 16.92 million common shares at $16.25 each, to raise $275.0 million.

03:14 01 Apr 2023 ETNB

89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study

Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.

10:49 01 Apr 2023 ETNB

Biotech Stock Surges on Mid-Stage Drug Trial Success

The shares of 89bio Inc ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biotech name revealed its experimental drug pegozafermin to treat nonalcoholic steatohepatitis (NASH) -- a type of fatty liver disease -- met the main objectives of a mid-stage study.

09:30 01 Apr 2023 ETNB

Why Is 89bio (ETNB) Stock Up 34% Today?

89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial. The goal of this study is to determine the effectiveness of pegozafermin in treating patients with NASH.

09:14 01 Apr 2023 ETNB

89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease

Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average. The post 89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease appeared first on Investor's Business Daily.

ETNB Financial details

Company Rating

Neutral

Market Cap

795.47M

Income

-102.03M

Revenue

Book val./share

4.36

Cash/share

5.41

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

09 May 2023

P/E

-6.94

Forward P/E

PEG

-4.2

P/S

P/B

4.72

P/C

2.82

P/FCF

-9.67

Quick Ratio

5.62

Current Ratio

5.81

Debt / Equity

0.3

LT Debt / Equity

0.13

EPS (TTM)

-5.22

EPS next Y

EPS next Q

EPS this Y

-34.6%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

278.95%

SMA20

11.52%

SMA50

37.18%

SMA100

65.58%

Inst Own

98.23%

Inst Trans

-1.77%

ROA

-52%

ROE

-90%

ROC

-0.62%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

52.23M

Shs Float

39.05M

Target Price

52W Range

2.0-18.03

52W High

-15.39%

52W Low

+661.5%

RSI

55.52

Rel Volume

1.26

Avg Volume

2.07M

Volume

2.6M

Perf Week

11.33%

Perf Month

11.82%

Perf Quarter

84.83%

Perf Half Y

164.41%

Beta

0.752094

Volatility

0.7%, 1.45%

Prev Close

2.28%

Price

15.23

Change

-3.73%

ETNB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-7.6	-24.49	-3.08	-5.6	-2.93
Operating cash flow per share	-5.86	-10.86	-2.87	-4.77	-2.33
Free cash flow per share	-5.88	-10.92	-2.88	-4.78	-2.33
Cash per share	5.28	39.82	12.72	9.37	5.41
Book value per share	-7.55	38.37	12.62	7.83	4.36
Tangible book value per share	-7.55	38.37	12.62	7.83	4.36
Share holders equity per share	-7.55	38.37	12.62	7.83	4.36
Interest debt per share	0	0	0	1.21	0.07
Market cap	44.25M	61.63M	392.06M	210.27M	443.08M
Enterprise value	33.01M	-31.71M	293.88M	177.23M	388.18M
P/E ratio	-2.74	-1.07	-7.92	-2.33	-4.34
Price to sales ratio	0	0	0	0	0
POCF ratio	-3.55	-2.42	-8.48	-2.74	-5.46
PFCF ratio	-3.54	-2.41	-8.46	-2.74	-5.46
P/B Ratio	-2.76	0.69	1.93	1.67	2.92
PTB ratio	-2.76	0.69	1.93	1.67	2.92
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-2.05	0.55	-5.94	-1.97	-3.84
EV to operating cash flow	-2.65	1.25	-6.35	-2.31	-4.79
EV to free cash flow	-2.64	1.24	-6.34	-2.31	-4.79
Earnings yield	-0.37	-0.93	-0.13	-0.43	-0.23
Free cash flow yield	-0.28	-0.42	-0.12	-0.37	-0.18
Debt to equity	-1.71	0.06	0.04	0.29	0.3
Debt to assets	2.41	0.06	0.04	0.22	0.23
Net debt to EBITDA	0.7	1.63	1.98	0.37	0.54
Current ratio	2.6	17	25.91	8.29	7.97
Interest coverage	0	0	0	0	-53.2
Income quality	0.77	0.44	0.93	0.85	0.79
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.01	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-6.5	-8.18	-2.1	-0.8	0.01
Stock based compensation to revenue	0	0	0	0	0
Graham number	35.94	145.42	29.55	31.41	16.96
ROIC	1.2	0.29	-3.9	-1.77	-1.39
Return on tangible assets	-1.42	-0.6	-0.23	-0.55	-0.52
Graham Net	-7.61	37.42	12.22	7.1	4.11
Working capital	6.96M	89.72M	202.09M	142.45M	171.47M
Tangible asset value	-16.06M	89.94M	202.96M	125.96M	151.83M
Net current asset value	-16.11M	89.72M	202.09M	125.52M	151.09M
Invested capital	0	0	0	0.15	0
Average receivables	0	0	0	0	0
Average payables	0	1.25M	1.53M	4.45M	9.67M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	1.01	-0.64	-0.24	-0.72	-0.67
Capex per share	-0.02	-0.06	-0.01	0	0

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-1.3	-1.26	-1.23	-0.57	-2.16
Operating cash flow per share	-1.39	-1.2	-0.73	-0.31	-1.9
Free cash flow per share	-1.4	-1.2	-0.73	-0.31	-1.9
Cash per share	7.44	6.2	6.85	4.09	5.41
Book value per share	6.22	5.05	3.94	3.23	4.36
Tangible book value per share	6.22	5.05	3.94	3.23	4.36
Share holders equity per share	6.22	5.05	3.94	3.23	4.36
Interest debt per share	0.96	0.96	0.97	0.42	0.07
Market cap	264.82M	76.68M	65.53M	273.6M	443.08M
Enterprise value	231.79M	41.26M	24.57M	221.22M	388.18M
P/E ratio	-2.52	-0.75	-0.65	-2.55	-1.47
Price to sales ratio	0	0	0	0	0
POCF ratio	-9.38	-3.15	-4.42	-18.47	-6.69
PFCF ratio	-9.37	-3.15	-4.42	-18.47	-6.68
P/B Ratio	2.1	0.75	0.82	1.79	2.92
PTB ratio	2.1	0.75	0.82	1.79	2.92
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-8.78	-1.62	-0.98	-8.26	-5.23
EV to operating cash flow	-8.21	-1.7	-1.66	-14.93	-5.86
EV to free cash flow	-8.2	-1.69	-1.66	-14.93	-5.86
Earnings yield	-0.1	-0.33	-0.38	-0.1	-0.17
Free cash flow yield	-0.11	-0.32	-0.23	-0.05	-0.15
Debt to equity	0.29	0.32	0.84	0.31	0.3
Debt to assets	0.22	0.24	0.46	0.24	0.23
Net debt to EBITDA	1.25	1.39	1.64	1.96	0.74
Current ratio	8.29	7.36	5.45	5.81	7.97
Interest coverage	0	0	0	0	-39.13
Income quality	1.07	0.95	0.59	0.55	0.88
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-1.29	-0.33	0.06	0	0.01
Stock based compensation to revenue	0	0	0	0	0
Graham number	13.47	11.95	10.45	6.42	14.56
ROIC	-0.51	-1.16	-1.15	-0.65	-1.02
Return on tangible assets	-0.16	-0.19	-0.17	-0.13	-0.38
Graham Net	5.64	4.58	3.53	3.08	4.11
Working capital	142.45M	117.01M	119.67M	165.43M	171.47M
Tangible asset value	125.96M	102.74M	80.19M	152.58M	151.83M
Net current asset value	125.52M	102.39M	79.16M	151.85M	151.09M
Invested capital	0.15	0.19	0.25	0.13	0
Average receivables	0	0	0	0	0
Average payables	9.68M	5.63M	4.66M	9.53M	13.33M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.21	-0.25	-0.31	-0.18	-0.5
Capex per share	0	0	0	0	0

ETNB Frequently Asked Questions

What is 89bio, Inc. stock symbol ?

89bio, Inc. is a US stock , located in San francisco of Ca and trading under the symbol ETNB

What is 89bio, Inc. stock quote today ?

89bio, Inc. stock price is $15.23 today.

Is 89bio, Inc. stock public?

Yes, 89bio, Inc. is a publicly traded company.

Something similar

Top by Market Cap

MSF.DE

AMZ.DE

Company Profile

Volume Average 2.07M
Market Capitalization 795.47M
Employee 41
CEO Mr. Rohan Palekar
Headquarters San Francisco,CA,US
IPO Date 2019-11-11
Website https://www.89bio.com

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.